Current Assets
Cash & Equivalents
Amgen Cash & Equivalents decreased by 7.5% to $559M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.0%, from $508M to $559M. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -5.5% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalContext dependent
VolatilityVolatile
First reportedQ4 2012
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase suggests strong liquidity or preparation for capital deployment, while a decrease may indicate heavy investment, debt repayment, or cash burn.
Detailed definition
Represents the most liquid assets held by the company, including currency, demand deposits, and short-term investments w...
Peer comparison
Standard across all industries; peers in biotech often hold high cash balances to fund R&D and clinical trials.
Metric ID:
cash_and_equivalentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $923M | $646M | $733M | $691M | $770M | $557M | $4.97B | $496M | $630M | $533M | $540M | $471M | $489M | $435M | $487M | $508M | $542M | $737M | $604M | $559M |
| QoQ Change | — | -30.0% | +13.5% | -5.7% | +11.4% | -27.7% | +792.3% | -90.0% | +27.0% | -15.4% | +1.3% | -12.8% | +3.8% | -11.0% | +12.0% | +4.3% | +6.7% | +36.0% | -18.0% | -7.5% |
| YoY Change | — | — | — | — | -16.6% | -13.8% | +578.0% | -28.2% | -18.2% | -4.3% | -89.1% | -5.0% | -22.4% | -18.4% | -9.8% | +7.9% | +10.8% | +69.4% | +24.0% | +10.0% |
Range$435M – $4.97B
CAGR-10.0%
Avg YoY Growth+29.6%
Median YoY Growth-7.4%
Current Streak2 quarters decline
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Amgen's cash & equivalents?
- Amgen (AMGN) reported cash & equivalents of $559M in Q1 2026.
- How has Amgen's cash & equivalents changed year-over-year?
- Amgen's cash & equivalents increased by 10.0% year-over-year, from $508M to $559M.
- What is the long-term trend for Amgen's cash & equivalents?
- Over 5 years (2020 to 2025), Amgen's cash & equivalents has grown at a -5.5% compound annual growth rate (CAGR), from $802M to $604M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid investments the company can access immediately.